1. Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation
- Author
-
Alan Chait, Antonio Sta. Teresa, Kevin D. O’Brien, Jinkyu Kim, Chang Yeop Han, Leela Goodspeed, Tomio Umemoto, Savitha Subramanian, Yilei Ding, and Shari Wang
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Saturated fat ,Adipose tissue ,macrophage ,QD415-436 ,Biology ,Real-Time Polymerase Chain Reaction ,Weight Gain ,Biochemistry ,Intestinal absorption ,Mice ,chemistry.chemical_compound ,Endocrinology ,Ezetimibe ,Internal medicine ,medicine ,Animals ,Cholesterol absorption inhibitor ,Serum amyloid A ,Research Articles ,Inflammation ,Mice, Knockout ,Cholesterol ,hepatic steatosis ,Macrophages ,Cell Biology ,Atherosclerosis ,Immunohistochemistry ,Intestines ,Mice, Inbred C57BL ,Adipose Tissue ,Intestinal Absorption ,Receptors, LDL ,chemistry ,Intestinal cholesterol absorption ,Azetidines ,lipids (amino acids, peptides, and proteins) ,Insulin Resistance ,medicine.drug - Abstract
Adipose tissue inflammation is associated with insulin resistance and increased cardiovascular disease risk in obesity. We previously showed that addition of cholesterol to a diet rich in saturated fat and refined carbohydrate significantly worsens dyslipidemia, insulin resistance, adipose tissue macrophage accumulation, systemic inflammation, and atherosclerosis in LDL receptor-deficient (Ldlr(-/-)) mice. To test whether inhibition of intestinal cholesterol absorption would improve metabolic abnormalities and adipose tissue inflammation in obesity, we administered ezetimibe, a dietary and endogenous cholesterol absorption inhibitor, to Ldlr(-/-) mice fed chow or high-fat, high-sucrose (HFHS) diets without or with 0.15% cholesterol (HFHS+C). Ezetimibe blunted weight gain and markedly reduced plasma lipids in the HFHS+C group. Ezetimibe had no effect on glucose homeostasis or visceral adipose tissue macrophage gene expression in the HFHS+C fed mice, although circulating inflammatory markers serum amyloid A (SSA) and serum amyloid P (SSP) levels decreased. Nevertheless, ezetimibe treatment led to a striking (85%) reduction in atherosclerotic lesion area with reduced lesion lipid and macrophage content in the HFHS+C group. Thus, in the presence of dietary cholesterol, ezetimibe did not improve adipose tissue inflammation in obese Ldlr(-/-) mice, but it led to a major reduction in atherosclerotic lesions associated with improved plasma lipids and lipoproteins.
- Published
- 2012
- Full Text
- View/download PDF